Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPain ManagementAetna ziconotide (Prialt) Coverage Update | OpenPa…
    Ask Trek AI about this page
    CurrentAetnaPolicy 0712

    Ziconotide (Prialt) Clinical Policy Bulletin

    Customize your policy alerts

    Sign up for Aetna Policy 0712 alerts

    Get alerted when Policy 0712 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines Aetna's medical necessity, contraindications, experimental/investigational uses, dosing recommendations, and applicable billing/coding for intrathecal ziconotide (Prialt) for severe chronic pain.

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Policy Summary
    PayerAetna
    PolicyZiconotide (Prialt) Clinical Policy Bulletin
    Policy CodePolicy 0712
    Change Typeclarified (references & policy history updated)
    Effective Date09/09/2005
    Last ReviewSep 21, 2023
    Next Review Date08/08/2024
    Key ActionProvider must document that member has severe chronic pain and is intolerant of or refractory to other treatments and confirm absence of pre-existing psychosis or other contraindications prior to IT ziconotide.
    SourceLink
    POLICY UPDATE CHANGES

    Last review dated 09/21/2023; effective date 09/09/2005; next review 08/08/2024.

    1Covered indication (severe chronic pain with prior treatment failure)
    3Main absolute contraindications listed
    7Experimental/Investigational indications listed
    40+References cited in Part 2

    Coverage Summary

    Defines Aetna's medical necessity, contraindications, experimental/investigational uses, dosing recommendations, and applicable billing/coding for intrathecal ziconotide (Prialt) for severe chronic pain. Aetna considers intrathecal (IT) administration of ziconotide medically necessary for adults with severe chronic pain when IT therapy is warranted and the pain is intolerant of or refractory to other treatments (e.g., systemic analgesics, adjunctive therapies, or IT morphine).

    Aetna highlights that ziconotide is delivered via an intrathecal infusion/pump, has a narrow therapeutic window requiring slow titration and careful monitoring, and is contraindicated in patients with a pre-existing history of psychosis or other contraindications to IT analgesia. The policy includes dosing thresholds, billing/coding guidance, and requirements for documentation and monitoring of neuropsychiatric adverse events.

    Quick thresholds & stats
    Initiation dose2.4 mcg/day titrated by day 21
    Maximum dose19.2 mcg/day
    Covered indication count1
    Contraindications count3
    Experimental indications count7
    References count40+

    Medical Necessity & Exclusions

    Medically Necessary

    Aetna considers intrathecal administration of ziconotide medically necessary when ALL of the following are met:

    ALL of the following

    • Member has severe chronic pain
    • Intrathecal therapy is warranted
    • Pain is intolerant of or refractory to other treatments such as systemic analgesics, adjunctive therapies, or intrathecal morphine

    Not Medically Necessary (Contraindications)

    Ziconotide intrathecal infusion is considered not medically necessary if ANY of the following contraindications are present:

    ANY of the following

    Relevant Codes

    Covered HCPCSHCPCSCovered
    J2278Injection, ziconotide, 1 mcg
    Covered ICD-10 (indications, when selection criteria met)ICD-10Covered
    G89.0Pain, not elsewhere classified
    G89.1Acute pain
    G89.2Chronic pain, not elsewhere classified
    G89.3Neoplasm related pain (acute) (chronic)
    G89.4Chronic pain syndrome
    Other related CPT codes (relevant to CPB procedures)CPT
    62320Injection(s), diagnostic or therapeutic substance(s), interlaminar epidural or subarachnoid, cervical or thoracic, lumbar or sacral (caudal), without imaging guidance
    62321with imaging guidance
    62322Injection(s) including needle or catheter placement, continuous infusion or intermittent bolus, interlaminar epidural or subarachnoid, without imaging guidance
    62323with imaging guidance
    62324Injection(s) including indwelling catheter placement, continuous infusion or intermittent bolus, interlaminar epidural or subarachnoid, cervical or thoracic, without imaging guidance
    62325with imaging guidance
    62326Injection(s) including indwelling catheter placement, continuous infusion or intermittent bolus, lumbar or sacral (caudal), without imaging guidance
    62327with imaging guidance
    62350Implantation, revision or repositioning of tunneled intrathecal or epidural catheter
    62351with laminectomy
    1–10 of 15
    1/2
    Other HCPCS / Equipment relatedHCPCS
    E0779Ambulatory infusion pump, mechanical, reusable, for infusion 8 hours or greater
    E0780Ambulatory infusion pump, mechanical, reusable, for infusion less than 8 hours
    E0781Ambulatory infusion pump, single or multiple channels, electric or battery operated, with administrative equipment, worn by patient
    E0783Infusion pump system, implantable, programmable (includes all components)
    E0785Implantable intraspinal catheter used with implantable infusion pump, replacement
    E0786Implantable programmable infusion pump, replacement (excludes catheter)
    Related opioid HCPCS (listed)HCPCS
    J2270Injection, morphine sulfate, up to 10 mg
    J2272Injection, morphine sulfate (Fresenius Kabi), up to 10 mg
    S0093Injection, morphine sulfate, 500 mg (loading dose for infusion pump)
    ICD-10 codes not covered for indications listed in the CPB (examples)ICD-10Not Covered
    C72.0Malignant neoplasm of spinal cord (spinal canal obstruction)
    D33.4Benign neoplasm of spinal cord (spinal canal obstruction)
    D69.9Hemorrhagic condition, unspecified (uncontrolled bleeding diathesis)
    F23Brief psychotic disorder
    F24Shared psychotic disorder
    F28Other psychotic disorder not due to a substance or known physiological condition
    F29Unspecified psychosis not due to a substance or known physiological condition
    F84.0Autistic disorder
    G12.23Primary lateral sclerosis
    G40.001Epilepsy and recurrent seizures (range begins)
    1–10 of 30
    1/3

    Provider Actions & Billing

    Documentation Required

    Document prior treatment failures

    Provider must document that member has severe chronic pain and is intolerant of or refractory to other treatments such as systemic analgesics, adjunctive therapies, or intrathecal morphine.

    • Documentation of severe chronic pain
    • Records of prior therapies tried (systemic analgesics, adjunctive therapies, intrathecal morphine) and intolerance or refractory response
    Documentation Required

    Screen for contraindications

    Provider must document absence of pre-existing psychosis and absence of contraindications to intrathecal analgesia (infection at infusion site, uncontrolled bleeding diathesis, spinal canal obstruction) prior to treatment.

    • Pre-existing history of psychosis (document absence)
    • Infection at the microinfusion/infusion site (document absence)
    • Uncontrolled bleeding diathesis (document absence)

    Background & Evidence

    Ziconotide (Prialt) is a synthetic, non-opioid N-type calcium channel blocker approved by the FDA for the management of severe chronic pain in adults for whom intrathecal (IT) therapy is warranted and who are intolerant of or refractory to other treatments. It is administered intrathecally via continuous infusion or implanted pump/catheter. Because ziconotide has a narrow therapeutic window, conservative initiation and slow titration are recommended (initiation dose 2.4 mcg/day titrated by day 21; maximum 19.2 mcg/day). Ziconotide carries warnings for severe psychiatric symptoms and neuropsychiatric adverse events (e.g., cognitive impairment, hallucinations, mood or consciousness changes), and patients with a pre-existing history of psychosis should not be treated with Prialt.

    Intrathecal (IT): Administration of medication into the spinal thecal (subarachnoid) space, typically via an implanted pump or catheter.

    Study / SourceSummary
    Randomized trial (Staats et al. 2004)Ziconotide provided statistically significant analgesia vs placebo in refractory pain (mean VASPI improvement 53.1% vs 18.1%, p < 0.001)
    Pilot/other studiesMultiple small studies and case series report analgesic activity with notable adverse events; pilot bolus study showed ~25% mean VAS reduction and other observational/case reports support use in select refractory patients

    Revision History

    09/09/2005clarified

    Policy effective date established as 09/09/2005.

    09/21/2023clarifiedLatest

    Last review dated 09/21/2023; Document Part 2 includes updated reference list and policy history entries.

    08/08/2024clarified

    Next scheduled review date set for 08/08/2024.

    Policy Summary
    PayerAetna
    PolicyZiconotide (Prialt) Clinical Policy Bulletin
    Policy CodePolicy 0712
    Change Typeclarified (references & policy history updated)
    Effective Date09/09/2005
    Last ReviewSep 21, 2023
    Next Review Date08/08/2024
    Key ActionProvider must document that member has severe chronic pain and is intolerant of or refractory to other treatments and confirm absence of pre-existing psychosis or other contraindications prior to IT ziconotide.
    SourceLink
    On This Page
    Coverage SummaryMedical Necessity & ExclusionsRelevant CodesProvider Actions & BillingBackground & EvidenceRevision History
  1. Contraindications to intrathecal (IT) analgesia include ONE of:: Pre-existing history of psychosis
  2. Contraindications to intrathecal (IT) analgesia include ONE of:: Infection at the microinfusion injection site
  3. Contraindications to intrathecal (IT) analgesia include ONE of:: Uncontrolled bleeding diathesis
  4. Contraindications to intrathecal (IT) analgesia include ONE of:: Spinal canal obstruction
  5. Experimental and Investigational (Not Covered)

    Intrathecal administration (or other routes) of ziconotide is considered experimental and investigational for the following indications because effectiveness has not been established:

    ANY of the following

    • Autism
    • Epilepsy
    • Irukandji syndrome
    • Migraines
    • Primary lateral sclerosis
    • Stroke
    • Intrathecal combination of ziconotide, morphine, and levobupivacaine for treatment of cancer-related refractory pain
  6. Spinal canal obstruction (document absence)
  7. Billing Rule

    Use J2278 for drug billing

    Report ziconotide dosing using HCPCS code J2278 (Injection, ziconotide, 1 mcg) when selection criteria are met.

    • Report J2278 (Injection, ziconotide, 1 mcg) for ziconotide drug billing when selection criteria are met
    Documentation Required

    Monitoring for neuropsychiatric AEs

    Providers should monitor patients frequently for cognitive impairment, hallucinations, or changes in mood or consciousness and interrupt or discontinue therapy if these occur.

    • Frequent monitoring for cognitive/psychiatric signs (cognitive impairment, hallucinations, mood or consciousness changes)
    • Interrupt or discontinue therapy if neuropsychiatric adverse events occur
    Documentation Required

    Periodic laboratory monitoring

    Periodic monitoring of serum creatine kinase is recommended due to potential elevation; evaluate patients for new neuromuscular symptoms.

    • Periodic serum creatine kinase (CK) monitoring
    • Evaluation for new neuromuscular symptoms (myalgias, muscle cramps, weakness, reduced activity)
    Note

    Policy review and references available

    Providers should reference the Clinical Policy Bulletin and supporting literature cited for clinical guidance and documentation supporting medical necessity determinations.

    • Clinical Policy Bulletin (Number: 0712) and cited references available for guidance and documentation to support medical necessity